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ABSTRACT 
Background: Twin-Twin Transfusion syndrome is associated with significant mortality and 
morbidity. Potential treatments require robust evaluation. The aim of this study was to 
evaluate outcome reporting across observational studies and randomised controlled trials 
assessing treatments for twin–twin transfusion syndrome (TTTS). 
 
Methods: Cochrane Central Register of Controlled Trials, EMBASE and Medline were 
searched from inception to August 2016. Observational studies and randomised controlled 
trials reporting outcomes following a treatment for TTTS in monochorionic-diamniotic twin 
pregnancies and monochorionic-triamniotic or dichorionic-triamniotic triplet pregnancies 
were included. We systematically extracted and categorised outcome reporting. 
 
Results: Six randomised trials and 94 observational studies, reporting data from 20,071 
maternal participants and 3,199 children, were included. Six different treatments were 
evaluated. Included studies reported sixty-two different outcomes, including 10 fetal, 28 
neonatal, 6 early childhood and 18 maternal outcomes. The outcomes were inconsistently 
reported across trials. For example, when considering offspring mortality, 31 studies (31%) 
reported live birth, 31 studies (31%) reported intrauterine death, 49 studies (49%) reported 
neonatal mortality, and 17 studies (17%) reported perinatal mortality. Four studies (4%) 
reported respiratory distress syndrome. Only 19 (19%) of studies were designed for long-
term follow-up and 11 of these studies (11%) reported cerebral palsy.  
 
Conclusions: Most studies evaluating treatments for TTTS, have often neglected to report 
clinically important outcomes, especially neonatal morbidity outcomes. Most studies are not 
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designed for long-term follow-up. The development of a core outcome set could help 
standardised outcome collection and reporting in Twin-Twin Transfusion syndrome studies. 
Registration Number: CRD42016043999.
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INTRODUCTION 
Twin-Twin Transfusion Syndrome (TTTS) is a unique pathology exclusive to monochorionic 
twin pregnancies whereby unbalanced transfusion across the placental vascular 
anastomoses leads to amniotic fluid volume imbalance between the twins. In severe TTTS 
the mortality rate is as high as 90% if untreated.2, 3Even with treatment, TTTS is still 
associated with an increased risk of perinatal mortality and morbidity compared to 
uncomplicated monochorionic pregnancies, with neurological and cardiac complications 
reported, as well as a significant risk of preterm birth and its associated complications.2-8 
 
The treatment options include fetoscopic laser surgery, amnioreduction, septostomy, 
expectant management and termination of pregnancy. Fetoscopic laser surgery now forms 
the mainstay of treatment and different techniques have also been compared.9 Given the 
high potential for morbidity and mortality in TTTS, there is a need for robust guidance on the 
safest course of management, particularly in the refinement of new treatment techniques. 
 
The importance of standardising randomised controlled trial methods has been recognised. 
However, the selection, collection, and reporting of outcomes has received less attention, 
despite it being a critical step in the design of randomised trials.10 Such outcomes should 
reflect both beneficial and harmful effects and need to be relevant to clinical practice and key 
stakeholders, including patients, healthcare professionals, and researchers. Evidence 
synthesis can be further hampered by different methods of measurement or definition, even 
when outcomes have been consistently collected across trials. For example, childhood 
neurodevelopmental impairment has been defined using different combinations of clinical 
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signs and cognitive assessments, performed with a range of tools, by different professionals 
and at different childhood ages.  
 
There is no consensus amongst key stakeholders on which outcomes should be collected 
and reported in studies of TTTS treatments. The first step in developing a core outcome set 
for TTTS requires an evaluation of the reporting of outcomes and outcome measures. The 
objective of the present study was therefore to assess the consistency of outcome reporting, 
including the adequacy of information pertaining to definition and measurement, among 




Protocol, eligibility criteria, information sources and search 
The protocol for this systematic review was registered prospectively on PROSPERO 
(International Prospective Register of Systematic Reviews); registration number: 
CRD42016043999.11 We have followed the reporting guidelines outlined by the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.12 
 
We searched Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and 
Medline from inception to August 2016 using MeSH descriptors including “twin-twin 
transfusion syndrome”, “twin-to-twin transfusion syndrome” and “fetofetal transfusion” 
(Supplementary Table 1). We included all randomised trials and observational studies 
reporting outcomes following a treatment for TTTS in monochorionic-diamniotic twin 
pregnancies and monochorionic-triamniotic and dichorionic-triamniotic triplet pregnancies. 
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We excluded case reports, review articles, meta-analysis, and systematic reviews. We 
applied no restriction for language or publication date and translated articles where 
necessary. 
 
Study selection, data collection and data items 
Two authors (HP and OU) independently screened all titles and abstracts in the search 
results. Studies were excluded if they did not fit the eligibility criteria and full texts were 
obtained for studies that were obviously eligible and those that could not be excluded based 
on title and abstract alone. These full text articles were critically reviewed for eligibility by two 
authors and any discrepancies were discussed and resolved with a third author.  
 
Data was extracted from the eligible studies using a standardised data collection tool. 
Variables collected included year of publication, publishing journal, study design, setting, 
participants, treatments, stage of TTTS and the funding source (if applicable) for the study. 
The impact factor was obtained from the International Scientific Institute’s Impact Factor List. 
A quality assessment was performed for each study. For randomised trials we used the 
Jadad scoring system and for observational studies we used the Newcastle-Ottawa scoring 
system.13,14 The size of the study was classified on either maternal or childhood participants, 
depending on the subject of the study. Due to the large number of relatively small single-
centre retrospective observational studies, we decided to include all randomised controlled 
trials and the largest 94 observational studies in the analysis. After full text review, we did 
not feel that including more studies would add to the variety of outcomes recorded. 
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Primary and secondary outcomes were recorded as well as their definition and instruments 
of measure. We considered and included outcomes listed as ‘variables collected’ if they 
were clearly documented in the abstract or methods section and reported in the results 
section. We did not include outcomes listed for the first time in the results section without 
any clear justification. An inventory of outcomes was produced and these were organised 
into the following categories: fetal outcomes, offspring mortality, neonatal outcomes, early 








Study selection and characteristics 
The search identified 1,209 articles. Forty-six duplicates were removed and 898 articles 
were considered not to meet inclusion criteria after title and abstract screening. Duplicates 
were defined as articles with the same title, authors and publishing journal and year. Of the 
898 articles that did not meet inclusion criteria 387 were unrelated to TTTS, 483 were not an 
intervention study (e.g. review, comment, case report) and in 28 cases the narrative did not 
fit the inclusion criteria (e.g. the paper did not report a discernible outcome). Two hundred 
and sixty-five articles were identified for full text review. Of these, 35 were further excluded 
as they either did not meet inclusion criteria (n=32) or full text could not be obtained (n=3).  
Two hundred and thirty studies were therefore deemed eligible after full text review and all 
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randomised trials (n=6) 9,15-19 and the largest observational studies (n=94)20-113 were selected 
for analysis (Figure 1). There were 13 case-control studies, 32 prospective cohort studies 
and 49 retrospective cohort studies. The included 100 studies reported data from 20,071 
maternal participants and 3199 children. 
 
Synthesis of the results 
Six different treatments were evaluated; fetoscopic laser surgery (95 studies; 95%), 
amnioreduction (15 studies; 15%), septostomy (1 study; 1%), expectant management (5 
studies; 5%), selective feticide (2 studies; 2%), and delivery (1 study; 1%). Eighty of the 
studies evaluated fetoscopic laser surgery alone, with three of these studies comparing 
different techniques of fetoscopic laser surgery; two studies compared the Solomon 
technique to the standard technique and one study compared different uterine entry 
techniques (sheath and trocar, cannula and trocar or cannula and Seldinger). Three studies 
evaluated adjuncts to fetoscopic laser surgery, including Nifedipine therapy, cervical 
cerclage and laparoscopic guidance, a single study evaluated amnioreduction alone and the 
remaining 16 studies compared two or more treatments with one of these studies including 
the adjunct of Digoxin therapy to amnioreduction. Full details of the studies and their 
treatments are shown in Table 1. 
 
Included trials reported 62 different outcomes, organised within six domains: six fetal 
outcomes, seven offspring mortality outcomes,  25 neonatal outcomes, six early childhood 
outcomes, eight maternal outcomes and 10 operative outcomes (Table 2). Regarding quality 
assessment, two of the randomised trials scored four out of five on the Jadad score and the 
remainder scored three out of five. None of them involved blinding due to the nature of the 
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treatments. Of the observational studies, only seven studies scored eight stars out of nine, 
nine studies scored seven stars, 38 score six stars, 30 scored six stars and ten scored four 
stars (Table 1). 
 
Concerning fetal outcomes, only 17 studies (17%) reported recurrence of TTTS (4206 
participants; 21.0%) and other fetal outcomes were even less reported. Offspring mortality 
was the most reported group, however there was inconsistency in the reported outcomes. 
Thirty-one studies (31%) reported live birth (5219 participants, 26%), 31 (31%) reported 
intrauterine death (6376 participants; 31.8%), 49 (49%) reported neonatal mortality (8216 
participants; 41%) and 17 (17%) reported perinatal mortality (3172 participants; 15.8%). 
Neonatal morbidity was reported with varying frequency with 33 studies (33%) reporting 
gestational age at delivery (reporting data from 5583 participants; 27.8%), 16 studies (16%) 
reporting intraventricular haemorrhage (reporting data from 3430 participants; 17.1%), six 
studies (6%) reporting necrotising enterocolitis (1023 participants; 5.1%) and four studies 
(4%) reporting respiratory distress syndrome (reporting data from 620 participants; 3.1%). 
Childhood outcomes were not commonly reported with only 19 studies reporting on 
outcomes beyond the neonatal period. Of these, 13 studies (13%) reported 
neurodevelopmental impairment and 11 studies (11%) reported cerebral palsy (1868 (9.3%) 
and 1459 (7.3%) participants, respectively). 
 
The most commonly reported maternal outcome was premature rupture of membranes 
which was reported by 31 studies (31%) (6057 participants; 30.2%). Operative complications 
were poorly reported with only six studies (6%) reporting haemorrhage (914 participants; 
4.6%) and one (1%) study reporting pain (175 participants; 0.9%). The full range of 
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outcomes reported is shown in Table 3. When considering the five randomised controlled 
trials and the 20 largest observational studies, 50% reported neonatal mortality, 30% 
reported premature rupture of the membranes and 15% reported on neurodevelopmental 
impairment in childhood (Table 4). 
 
There was variation of the definitions of reported outcomes. For neonatal mortality/survival, 
five different definitions were found, but in 47% of studies where neonatal mortality/survival 
was reported as an outcome, no definition was given. Seven different definitions were 
identified for premature rupture of membranes and eight for childhood neurodevelopmental 
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DISCUSSION 
Summary of main findings 
We have found wide variation and inconsistencies in the reporting of maternal and offspring 
outcomes. Of six randomised controlled trials and 94 observational studies, reporting data 
from 20,071 maternal participants, less than a third reported live birth or intrauterine death 
as an outcome. Whilst 49% of studies reported neonatal mortality/survival as an outcome, 
there were five different definitions of this and almost half of these studies did not define this 
outcome. Neonatal morbidity was poorly reported with only four studies reporting respiratory 
distress syndrome, a common morbidity associated with prematurity, as an outcome. Only 
19 studies were designed for follow-up beyond the neonatal period and 13 of these reported 
on childhood neurological outcome. Despite the mainstay of treatments for TTTS being 
surgical, maternal and operative outcomes were not commonly reported, with haemorrhage 
only reported by 6% of studies and pain by 1%.  
 
Strengths and Limitations 
The strengths of this study are in its robust methodology. Following prospective registration, 
with pre-determined outcomes, an independent search was performed without limits on date 
or language and we translated articles where necessary, to be as inclusive as possible. 
Study selection and data extraction was performed independently by two authors to limit 
bias.  
 
This study is limited in its ability to garner patient-important outcomes, which may not be 
best evaluated from randomised controlled trials or observational studies. Further qualitative 
research, such as structured interview-based studies, is required to overcome this. To 
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further reduce bias in the review process, we could have blinded the reviewers to details of 
the articles, such as authors, year of publication and publication journal. By limiting the final 
analysis to the randomised trials and 94 largest observational studies we may have missed 
out on outcomes reported by the smaller studies, which were not reported by larger studies. 
However, with the inclusion of 62 outcomes across seven domains, we feel this review is 
reflective of current studies of treatment for TTTS. Our study may underestimate consistency 
in outcome reporting due to our methodology of reporting all studies singularly even if they 
were from the same centre. It is possible that different publications were used to report 
different outcomes from the same centres. Similarly, by only including outcomes and 
recorded variables clearly defined in the abstract and methods section, we may have under-
reported some outcomes if they were only mentioned for the first time in the results section. 
Our rationale for this is that any outcomes that the researchers planned to report would 
normally be outlined in advance. We had a consistent approach to all studies reviewed and 
feel we have highlighted that different studies prioritise different outcomes resulting in wide 
variation in outcome reporting. 
 
Interpretation of findings 
Our search only identified six randomised controlled trials reporting outcomes after treatment 
for TTTS, reflecting the fact that due to the relatively low prevalence of this condition, it is 
difficult to perform large, good quality trials. With this in mind, it is of paramount importance 
that any studies that are undertaken collect data on relevant outcomes which can be 
interpreted in relation to existing literature and results can be easily compared.114 Previous 
studies have also found variation and inconsistency in the reporting of outcomes in different 
areas of women’s health including preeclampsia, preterm birth, and endometriosis.115-119 
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One possible reason for this diversity in outcome reporting in TTTS is the emergence of a 
leading new treatment (fetoscopic laser surgery) over the last 20 years. As the risk of fetal 
mortality in TTTS is so high, pioneers of this treatment primarily focused on survival to birth 
as an outcome, with less regard to other outcomes that may be considered important by 
stakeholders. The fact that many different centres were publishing their results 
independently as relatively small observational studies probably compounded this effect.  
 
With improving rates of survival to birth, there is now increased interest in the neonatal and 
longer term morbidity for surviving children and with any treatment for a fetal disease, 
consideration should also be given to the effects on the mother.  This systematic review 
highlights that to date, these outcomes have not been consistently reported with only 19 of 
the 100 studies designed to obtain outcomes beyond the neonatal period. We feel that any 
centre performing treatment for TTTS should have access to neonatal outcomes, yet with 
the exception of neonatal mortality, these were not commonly reported. Outcomes such as 
necrotising enterocolitis are likely to be considered important by parents. This issue is not 
unique to TTTS; in a systematic review of outcome reporting in preterm birth, only one (1%) 
randomised trial reported composite morbidity in the neonatal period or at follow-up and 
none reported on maternal morbidity and mortality. Similarly, in a systematic review of 
outcome reporting in preeclampsia, the authors found that only 6 (7.6%) of randomised trials 
reported childhood outcomes. 115,116 Bias may be introduced in the selection of primary 
outcomes in the first place, as researchers are influenced by factors including sample size 
requirement, time until an outcome can be reported and cost. This can lead to more 
accessible but less informative outcomes being selected.120 
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The Core Outcomes in Women’s and Newborn Health (CROWN) initiative aims to facilitate 
consistent recording and reporting of outcomes by working closely with journals, 
researchers, funders and patients  to develop core outcome sets for specific diseases.121, 122  
Several core outcome sets are in development across obstetrics including for: gastroschisis, 
fetal monitoring and stillbirth.123 The Core Outcome Measures in Effectiveness Trials 
(COMET) Initiative suggests three stages to developing a core outcome set: (1) identifying 
potential core outcomes; (2) determining core outcomes using robust consensus methods 
engaging key stakeholders; and (3) determining how core outcomes should be measured.124 
In line with the CROWN and COMET initiatives, we have previously described our intention 
to develop a core outcome set for TTTS and the inventory of outcomes identified by this 
systematic review will be entered into a Delphi Method for the second stage of the process. 
Key stakeholders including researchers, clinicians and patients will be invited to participate 
in this consensus-forming exercise.125 This process has worked successfully in the 
development of core outcome sets for other related conditions, including abortion, pre-
eclampsia, neonatal care, and endometriosis.126-129 For example, regarding preterm birth, 
174 participants from five stakeholder groups reviewed and scored 31 outcomes via Delphi 




Most studies reporting outcomes following treatment for TTTS are observational in nature 
and report many different outcomes, with varying definitions. These inconsistencies 
contribute to an inability to compare, contrast, and combine results and inform decision 
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making in a clinical context. Developing a clinically relevant core dataset for implementation 
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Records screened (titles and abstract) n=1163 
Duplicates removed n=46 
Records excluded              n=898 
Unrelated to TTTS               n=387 
Not an intervention study     n= 483 
Narrative                              n= 28 
Full text articles assessed for eligibility  n=265 
Studies eligible    n = 230 
Excluded studies  n=35 
Unrelated to TTTS                       n= 6 
Not an intervention study  n =25 
Narrative    n = 1 
Unable to source    n = 3 
Largest 100 Studies included 
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This article is protected by copyright. All rights reserved.










369  Fetoscopic Laser 
Surgery 
  6* 









54 91 Fetoscopic Laser 
Surgery 
  6* 





92  Fetoscopic Laser 
Surgery 
  6* 





154  Fetoscopic Laser 
Surgery 
  6* 





85  Fetoscopic Laser 
Surgery 
  5* 



















57 100 Fetoscopic Laser 
Surgery 
  6* 





90  Fetoscopic Laser 
Surgery 
  6* 




1-4 at < 17 
weeks 
gestation 
178  Fetoscopic Laser 
Surgery 
  6* 





340  Fetoscopic Laser 
Surgery 
  7* 









219 318 Fetoscopic Laser 
Surgery 
  5* 





610  Fetoscopic Laser 
Surgery 
  4* 





252  Fetoscopic Laser 
Surgery 
  5* 





215  Fetoscopic Laser 
Surgery 





TTTS cases  328  Fetoscopic Laser 
Surgery 
  6* 





102  Fetoscopic Laser 
Surgery 
  8* 





134  Fetoscopic Laser 
Surgery 
  8* 





147  Fetoscopic Laser 
Surgery 
  8* 




1-4 at < 17 
weeks 
gestation and 
> 26 weeks 
gestation 
325  Fetoscopic Laser 
Surgery 
  4* 





507  Fetoscopic Laser 
Surgery 
  6* 
This article is protected by copyright. All rights reserved.
   





















1-4 < 28 weeks 
gestation 
81  Fetoscopic Laser 
Surgery  
Amnioreduction  6* 





148  Fetoscopic Laser 
Surgery 
  5* 









200 190 Fetoscopic Laser 
Surgery 
  4* 





120  Fetoscopic Laser 
Surgery 
  6* 





262  Fetoscopic Laser 
Surgery 








94  Fetoscopic Laser 
Surgery 
  5* 







648  Fetoscopic Laser 
Surgery 
  5* 







534  Fetoscopic Laser 
Surgery 
  7* 





195  Fetoscopic Laser 
Surgery 
  4* 





150 172 Fetoscopic Laser 
Surgery 
  6* 





123  Expectant 
management  
Amnioreduction  5* 







77  Fetoscopic Laser 
Surgery 
  6* 





196 256 Fetoscopic Laser 
Surgery 
  4* 





682  Fetoscopic Laser 
Surgery 








414  Fetoscopic Laser 
Surgery 
  5* 







181 163 Fetoscopic Laser 
Surgery 
  5* 









75 113 Fetoscopic Laser 
Surgery 








293  Fetoscopic Laser 
Surgery + 
Nifedipine 
  5* 




2-4< 26 weeks 
164  Fetoscopic Laser 
Surgery 
  6* 
This article is protected by copyright. All rights reserved.
   







267  Fetoscopic Laser 
Surgery 
  5* 





97  Fetoscopic Laser 
Surgery 
  8* 







99  Fetoscopic Laser 
Surgery 
  6* 





79  Fetoscopic Laser 
Surgery 
  6* 







152  Fetoscopic Laser 
Surgery 
  6* 














209 312 Fetoscopic Laser 
Surgery  
Amnioreduction  7* 















100  Fetoscopic Laser 
Surgery 
  5* 









212 278 Fetoscopic Laser 
Surgery 
  8* 





163  Fetoscopic Laser 
Surgery 
  5* 






<15mm prior to 
surgery 
272  Fetoscopic Laser 
Surgery with 
emergency 













82  Fetoscopic Laser 
Surgery 
  7* 




1-4 with dual 
neonatal 
survivors born 
at least 28 
days after 
surgery  
211  Fetoscopic Laser 
Surgery 
  6* 






438  Fetoscopic Laser 
Surgery 
  4* 





176  Fetoscopic Laser 
Surgery 
  8* 





287  Fetoscopic Laser 
Surgery 
  6* 









  6* 





193  Fetoscopic Laser 
Surgery 
  6* 
This article is protected by copyright. All rights reserved.
   
weeks 
gestation 

















209  Fetoscopic Laser 
Surgery  
Amnioreduction  7* 







100  Fetoscopic Laser 
Surgery 
  6* 







82 115 Fetoscopic Laser 
Surgery 
  6* 







101  Fetoscopic Laser 
Surgery 
  5* 




3-4, <26 weeks 
gestation 
77  Fetoscopic Laser 
Surgery 
  6* 




1-4, <26 weeks 
gestation 
200  Fetoscopic Laser 
Surgery 
  6* 
 







108  Fetoscopic Laser 
Surgery 
  6* 





120  Fetoscopic Laser 
Surgery 
  4* 





alive 1 week 
after treatment 
151  Fetoscopic Laser 
Surgery 
  6* 







127 167 Fetoscopic Laser 
Surgery 
  5* 







73 89 Fetoscopic Laser 
Surgery 
  6* 






86  Fetoscopic Laser 
Surgery 
  7* 





175  Fetoscopic Laser 
Surgerv 
  5* 





with at least 1 
survivor after 
treatment 
98  Fetoscopic Laser 
Surgery 
  5* 





173  Fetoscopic Laser 
Surgery  
Amnioreduction  4* 







73 89 Fetoscopic Laser 
Surgery 
  5* 





223  Amnioreduction   6* 






200  Fetoscopic Laser 
Surgery 
  6* 
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Table 1: Characteristics of included studies 
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Outcome Reporting studies 
(n=100) 
Number of maternal participants  
(n=20071) 
   
FETAL OUTCOMES   
Disease progression   
Recurrence of twin-twin transfusion syndrome, n (%)  17 (17) 4206 (21.0) 
Cardiovascular morbidity   
Fetal Echo Abnormalities, n (%)  4 (4) 1108 (5.5) 
Anaemia, n (%)  1 (1) 120 (0.6) 
Neurological morbidity   
Cerebral lesions, n (%)  4 (4) 1592 (7.9) 
Other   
Amniotic Band Syndrome, n (%)  4 (4) 1278 (6.4) 
Twin anaemia polycythaemia syndrome, n (%)  14 (14) 3738 (18.6) 
   
OFFSPRING MORTALITY   
Live birth, n (%)  31 (31) 5219 (26.0) 
Miscarriage, n (%)   11 (11) 1419 (7.1) 
Intrauterine death, n (%)  31 (31) 6376 (31.8) 
Neonatal mortality/survival, n (%)   49 (49) 8216 (41.0) 
Perinatal mortality/survival, n (%)   17(17) 3172 (15.8) 
Early childhood mortality, n (%)   9 (9) 1083 (5.4) 
Termination of Pregnancy, n (%)  2 (2) 227 (1.1) 
   
NEONATAL OUTCOMES   
Delivery   
Gestational age at delivery, n (%)   33 (33) 5583 (27.8) 
Mode of delivery, n (%)  7 (7) 2098 (10.5) 
Birth weight, n (%)  14 (14) 2155 (10.7) 
Apgar scores, n (%)  3 (3) 365 (1.8) 
Neurological morbidity   
Stroke, n (%)  4 (4) 860 (4.3) 
Intraventricular haemorrhage, n (%)  16 (16) 3430 (17.1) 
Periventricular leukomalacia, n (%)  17 (17) 3594 (17.9) 
Ventriculomegaly, n (%)  11 (11) 2297 (11.4) 
Cystic Lesions, n (%)  7 (7) 1651 (8.2) 
Retinopathy of prematurity, n (%)  3 (3) 510 (2.5) 
Cardiovascular morbidity   
Pulmonary stenosis, n (%)  1 (1) 260 (1.3) 
Pulmonary atresia, n (%)  1 (1) 260 (1.3) 
Persistent Pulmonary Hypertension of the Newborn, n (%)  1 (1) 195 (1.0) 
Congenital heart disease, n (%)  1 (1) 101 (0.5) 
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Hypotension, n (%)  2 (2) 290 (1.4) 
Ischaemic Limb Injury, n (%)  2 (2) 360 (1.8) 
Respiratory morbidity    
Respiratory distress syndrome, n (%)  4 (4) 620 (3.1) 
Chronic lung disease/Bronchopulmonary Dysplasia, n (%)  6 (6) 1044 (5.2) 
Intubation and ventilation, n (%)  1 (1) 209 (1.0) 
Pulmonary hypoplasia, n (%)  1 (1) 81(0.4) 
Gastrointestinal morbidity   
Necrotising enterocolitis, n (%)  6 (6) 1023 (5.1) 
Genitourinary morbidity   
Renal failure, n (%)  4 (4) 599 (3.0) 
Infectious morbidity    
Sepsis, n (%)  3 (3) 826 (4.1) 
Interventions to manage morbidity   
Parenteral nutrition, n (%)  1 (1) 81 (0.4) 
Resuscitation of the neonate, n (%)  1 (1) 81 (0.4) 
   
EARLY CHILDHOOD OUTCOMES   
Neurodevelopment   
Visual impairment, n (%)   10 (10) 1430 (7.1) 
Hearing impairment, n (%)  9 (9) 1424 (7.1) 
Cerebral palsy, n (%)   11 (11) 1459 (7.3) 
Neurodevelopmental Impairment, n (%)  13 (13) 1868 (9.3) 
Cardiovascular morbidity   
Hypertension, n (%)  1 (1) 54 (0.3) 
Cardiac dysfunction, n (%)  1 (1) 73 (0.4) 
   
MATERNAL OUTCOMES   
Maternal mortality, n (%)  2 (2) 409 (2.0) 
Mirror syndrome, n (%)  3 (3) 578 (2.9) 
Premature rupture of membranes, n (%)  31 (31) 6057 (30.2) 
Chorioamnionitis, n (%)  8 (8) 2078 (10.4) 
Placental abruption, n (%)  6 (6) 1346 (6.7) 
Amniotic fluid embolism, n (%)  1 (1) 142 (0.7) 
Preterm birth, n (%)  8 (8) 1857 (9.3) 
Pulmonary oedema, n (%)  3 (3) 718 (3.6) 
   
OPERATIVE COMPLICATIONS   
Pain, n (%)  1 (1) 175 (0.9) 
Hypotension, n (%)  1 (1) 328 (1.6) 
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Haemorrhage, n (%)  6 (6) 914 (4.6) 
Blood transfusion, n (%)  3 (3) 794 (4.0) 
Emergency laparotomy, n (%)  1 (1) 176 (0.9) 
Unintentional membrane separation, n (%)   5 (5) 830 (3.3) 
Unintentional septostomy, n (%)  4 (4) 814 (4.1) 
Intraabdominal amniotic fluid leak, n (%)  5 (5) 753 (3.8) 
Admission to intensive care, n (%)  3 (3) 651 (3.2) 
Operative Time, n (%)  3 (3) 552 (2.8) 
 
Table 3: Maternal and offspring outcome reporting across randomised trials and observational studies.
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Study                                          
Randomised trials                                          
Van-Klink, 2016                                      X X X X 
Slaghekke, 2014 X    X X     X     X  X     X X       X  X X X X      
Salomon, 2010           X                           X  X X 
Crombleholme, 2007          X                                
Moise, 2005       X   X                   X             
Senat, 2004        X X X X X    X    X    X X X       X X    X X   
Observational studies                                          
Stirnemann, 2016 X   X  X                                    
Chmait, 2011         X X                                
Peterson, 2016                       X    X               
Stirnemann, 2012 X     X   X X              X X    X    X X        
Michelfelder, 2014  X     X                                   
Spruijt, 2012                                 X X X X      
Stirnemann, 2013           X                               
Van kempen, 2016                       X      X X X      X     
Winer, 2008         X              X      X             
Cruz-Martinez, 2011     X    X          X    X      X X            
Van Winden, 2015         X X                 X   X            
Peeters, 2014           X   X                            
Lenclen, 2009                                      X X X X 
Ngamprasertwong, 2013       X        X                           
Baud, 2013       X   X       X    X X      X              
Quarello, 2007    X   X  X X                                
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Crombleholme, 2010  X     X          X       X    X              
Stirnemann, 2008 X         X                                
Eschbach, 2016         X                                 
Salomon, 2008          X             X X     X             
 
Table 4: Inconsistency in outcome reporting across randomised trials and the 20 largest observational studies. 
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Outcome Measure Number (%) Number (%) 
Total 100 20071 
   
Live birth 31 (31) 5219 (26.0) 
Survival to birth  10 (10) 1865 (9.3) 
Not defined  21 (21) 3354 (16.7) 
   
Miscarriage 11 (11) 1419 (7.1) 
Pregnancy loss < 24 weeks  6 (6) 828 (4.1) 
Not defined  5 (5) 591 (2.9) 
   
Intrauterine Death 31 (31) 6376 (31.8) 
Absence of fetal heart activity on ultrasonography after the procedure and before the onset of labour  1 (1) 154 (0.8) 
Death occurring between diagnosis and birth 1 (1) 81 (0.4) 
Death within 7 days of surgery  1 (1) 215 (1.1) 
Not defined  28 (28) 5926 (29.5) 
   
Neonatal Mortality/Survival 49 (49) 8216 (41.0) 
Survival to discharge  4 (4) 527 (1.9) 
Death within 7 days of birth  2 (2) 415 (2.1) 
Number of fetuses surviving 6 months postnatally  1 (1) 82 (0.4) 
Death between birth and 28 days postnatally  13 (13) 2450(7.4) 
Survival to 30 days postnatally  6(6) 1727 (7.2) 
Not defined  23 (23) 3015(13.9) 
   
Perinatal mortality/Survival 17 (17) 3172 (15.8) 
Number of fetuses who died at >20 weeks of gestation together with infants who died at <28 days of life  1 (1) 209 (1.0) 
Death between diagnosis and 28 days post-natally  3 (3) 730 (3.6) 
Survival at 30 days  1 (1) 193 (1.0) 
Either fetal demise or neonatal death  2 (2) 352 (1.8) 
Survival to 28 days or beyond  2 (2) 654 (3.3) 
Not defined  8 (8) 1034 (5.2) 
   
Early childhood mortality 9 (9) 1083 (5.4) 
Alive at 6 months 3 (3) 488 (2.4) 
Alive at 7-12 months  1 (1) 142 (0.7) 
Alive at 12 months  3 (3) 255 (1.3) 
Not defined  2 (2) 198 (1.0) 
   
Termination of Pregnancy 2 (2) 227 (1.1) 
Not defined  2 (2) 227 (1.1) 
This article is protected by copyright. All rights reserved.
   
   
PROM 31 (31) 6057 (30.2) 
Rupture of membranes < 24 hours post procedure, within 7 days and within 1-4 weeks of procedure  2 (2) 218 (1.1) 
Rupture of membranes within 3 weeks of procedure  1 (1) 267 (1.3) 
Rupture of membranes diagnosed clinically ≤ 34 weeks' gestation and prior to the onset of spontaneous labour  7 (7) 982 (4.9) 
Rupture of membranes < 32 weeks gestation  2 (2) 592 (2.9) 
Rupture of membranes before the beginning of the first stage of labour  1 (1) 94 (0.5) 
Rupture of membranes > 24 weeks  1 (1) 150 (0.7) 
Rupture of membranes < 37 weeks  1 (1) 164 (0.8) 
Not defined   16 (16) 3590 (14.1) 




Visual impairment  10 (10) 1430 (7.1) 
Bilateral blindness  5 (5) 878 (4.4) 
Complete blindness  1 (1) 150 (0.7) 
Previous clinical report or Amiel-Tison examination 1 (1) 57 (0.3) 
Not defined  3 (3) 345 (1.7) 
   
Hearing impairment  9 (9) 1424 (7.1) 
Bilateral deafness requiring amplification  5 (5) 1000 (5.0) 
Complete deafness  1 (1) 150 (0.7) 
Previous clinical report or Amiel-Tison examination  1 (1) 57 (0.3) 
Not defined  2 (2) 217 (1.1) 
   
Cerebral palsy  11 (11) 1459 (7.3) 
According to the European CP Network definition 6 (6) 1006 (5.0) 
According to the criteria of Mutch et al. 1 (1) 75 (0.4) 
On Amiel-Tison Neurodevelopmental Examination  1 (1) 57 (0.3) 
Not defined  3 (3) 321 (1.6) 
   
Neurodevelopmental Delay 13 (13) 1868 (9.9) 
A Bayley BSID-II score > 2SD below mean = severe delay and >1SD below mean= mild/moderate delay 1 (1) 156 (0.8) 
Presence of cerebral palsy, cognitive impairment, bilateral blindness, or deafness requiring amplification with 
hearing aids  
2 (2) 157 (0.8) 
Presence of cerebral palsy, a mental developmental indices score below 70, a psychomotor development indexes 
score below 70 (Bayley BSID-II), bilateral blindness, or bilateral deafness requiring amplification  
2(2) 431 (2.2) 
Having bilateral blindness (unable to fix on or track an object), bilateral deafness (requiring amplification), cerebral 
palsy (based on physical exam), and/or a Battelle Developmental Inventory, Second Edition (BDI-2) Total 
Developmental Quotient of <70  
2 (2) 114 (0.6) 
An Ages and Stages Questionnaire (ASQ) score <2 SD below the established average score 1 (1) 209 (1.6) 
A score of > 2 SD below the mean on Snijders–Oomen non-verbal intelligence test or Griffiths' developmental test 2 (2) 323 (1.6) 
Cerebral palsy with neurological abnormalities including hemiparesis, spastic quadriplegia, and blindness  1 (1) 128 (0.6) 
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Motor deficits impairing their ability to walk, complete blindness or deafness, Griffiths DQ (developmental quotient) 
< 70 and/or severe behavioral disorder  
1 (1) 150 (0.7) 
Not defined 1 (1) 200 (1) 
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